Golimumab biosimilar (Reliance Life Sciences)

戈利木单抗生物类似药 (Reliance Life Sciences)

Report date: 2025/01/06 14:18:23

Base Information

Drug NameGolimumab biosimilar (Reliance Life Sciences)
Drug Alias NameRTPR-044
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesReliance Life Sciences
China Registration ClassN/A

Develop Information

Active CompaniesReliance Life Sciences
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A